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Abstract 
 
Background 
Pseudomonas aeruginosa bloodstream infections (BSI) are associated with substantial short term 
mortality.  There are few data on long term mortality in this infection.   
Aim 
The aim of this study was to describe mortality rates out to one year post infection and the significant 
factors associated with death.   
Methods 
Positive blood cultures for P. aeruginosa were identified from January 2008 to January 2011 at 7 
tertiary care hospitals.  Extensive epidemiological, clinical and outcome data were obtained.   
Findings 
Three hundred and eighty eight BSI episodes were included in the analysis. The majority of infection 
was hospital-acquired.  The most common patient co-morbidities were haematological or oncological.   
Seventy eight percent of the cohort had received a medical device in the preceding 7 days.  Sixty one 
percent of the cohort received adequate empirical therapy.   All-cause mortality was 4% at 48 hours, 
19% at one month and 38% at one year.  Forty-eight hour mortality was associated with a non-hospital 
acquired infection, a pulmonary co-morbidity, corticosteroid therapy in the proceeding 30 days and a 
Pitt bacteremia score of greater than 2.  Co-morbidities became significantly associated with mortality 
from 7 days post infection.  Long-term mortality (defined as 1 year mortality) was associated with 
female sex, a haematological or oncological comorbidity, a chronic co-morbidity index of greater than 
2 and recent corticosteroid therapy.     
Conclusion 
The exact role of infection from a highly virulent pathogen, in the cause of death overtime needs to be 
studied further.  It is not clear if we are dying from or with this infection. 
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Introduction 
Pseudomonas aeruginosa bloodstream infections (BSI) are associated with significant morbidity and 
mortality.  Mortality rates of up to 42% have been described, depending on the patient population 
studied and the time at which mortality endpoint is determined.1-5  The majority of studies focusing on 
P. aeruginosa BSI have only looked at mortality out to one month post infection.  A population based 
study by Al-Hasan et al in 2008 looked at mortality at 28 days and found a mortality of  25.5%.  This 
increased to 47.5% at one year.6   
 
Nielsen et al examined the specific cause attributed to death over a 12 year period in all cause 
bacteraemias.  They found a significantly increased all-cause mortality rate ratio out to ten years in the 
patients with a bacteraemia.7  Davis et al prospectively looked at outcomes to 5 years following 
hospital admission for sepsis using relative survival analysis.  Australian life tables were used as the 
reference population.  They found that mortality based on cumulative relative survival exceeded that of 
the reference population for the first two years post admission in the whole cohort.  On multivariate 
analysis, predictors of excess mortality included being bacteremic which had a hazard ratio of 1.67 
(1.15-2.42, p<0.05).8   
 
P. aeruginosa only makes up a small number of the infections contributing to the overall cohort in the 
all-cause bacteraemia studies.7,9,10  The exact role of infection from this highly virulent pathogen in the 
cause of death overtime needs to be studied further.  The aim of this study was to look at the 
longitudinal mortality in this infection and the factors associated with death at each of the time points 
studied.   
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Materials and Methods 
 
Study design 
The study was conducted at 7 tertiary care hospitals in Brisbane, Australia. The hospitals range in size 
from 207 to 929 beds.  Together they provide a specialised and broad medical, surgical and intensive 
care for an urban population of 2.24 million.  Positive blood cultures for P. aeruginosa were identified 
over the 3 year time period of January 2008 to January 2011 from the laboratories servicing the 
hospitals. A BSI episode was identified as the 14 day time period from the date of the first positive 
blood culture.11  Patients were excluded if they met any of the following criteria: age less than 18 years, 
the blood culture growth was poly-microbial (excluding skin flora) or there was growth of another 
significant blood pathogen from 10 days prior to 14 days after the collection of the sentinel blood 
culture, the patient was not admitted to hospital post blood culture collection, the sentinel blood culture 
was not taken at a participating hospital, there was no antibiotic treatment of the blood culture isolate, 
the patient was transferred to another institution within 72 hours of the primary blood culture being 
collected, or the patient’s case notes could not be obtained. Episodes of recurrent infection were also 
excluded from the analysis.   Ethics approval to carry out the study from all participating hospitals and 
laboratories was obtained.  
 
Data Collection and Definitions 
Assessed clinical variables 
The following data were collected from all patient case notes in a retrospective fashion: age, sex, origin 
of infection (hospital, health-care or community acquired), co-morbidities, Charlson’s weighted 
comorbidity index (CCI), invasive medical devices in the 7 days prior to the episode, surgery in the 14 
days prior to the episode, immunosuppressive therapy or blood products in the 30 days prior to the 
episode, source of the bacteraemia, antimicrobial therapy started from 30 days prior to post primary 
bacteraemia,  the Pitt bacteraemia score and  the length of hospital stay post bacteraemia onset.12,13  
Immunosuppressive therapy referred to any drug classes that suppress the immune system and was 
divided into chemotherapy agents, any corticosteroid therapy, TNF blockers and other.  The latter 
category referring to such agents as tacrolimus, calcineurin inhibitors, mycophenolate, 
immunosuppressive antibodies or interferon.  For 14 days from the date of the sentinel blood culture,  
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daily temperature, daily  lowest systolic blood pressure and if any pressor therapy was used was also 
recorded.  From the laboratory, details of any other blood culture isolates from 10 days prior to 30 days 
post the episode were obtained. In addition antibiograms of the P. aeruginosa isolates of interest, other 
sites of growth of P. aeruginosa within 48 hours before or after positive blood cultures for P. 
aeruginosa and daily white blood cell count were recorded.  Mortality data, regarding whether the 
patient was deceased or not, was obtained from either documentation of a patient’s death in the case 
notes, evidence of a patient’s autopsy results on the relevant laboratory database, date of death recorded 
as part of the public hospital discharge summary database across public hospitals in Queensland, the 
Courier Mail funeral notices or from the Queensland Registry of Births, Deaths and Marriages.   These 
data were recorded for the time points post sentinel BSI of 48 hours, 7 days, 28 days and 1 year.     
 
 
Definitions 
A bacteremic episode is defined as the 14 day time period from the date of the first positive blood 
culture for P. aeruginosa.  Positive blood cultures outside this time constitute a different episode.   
A hospital acquired infection (HAI) is defined as a positive blood culture obtained from a patient after 
48 hours of hospitalisation or within 48 hours of discharge.  A healthcare associated infection (HCAI) 
is defined as a positive culture obtained from a patient at the time of hospital admission or within 48 
hours of admission if the BSI fulfilled any of the following criteria: 1. Is a complication of an 
indwelling medical device; 2. Occurs within 30 days of a surgical procedure where the BSI is related to 
a surgical site infection; 3. An invasive instrumentation with or without an associated procedure, 
related to a BSI, was performed within 48 hours before the onset of infection. If the timing of onset was 
longer than 48 hours there must be compelling evidence that the infection was related to an invasive 
device or procedure; 4. Received therapy with temporary intravenous access in the 48 hours before the 
onset of infection.  If the timing of onset was longer than 48 hours there must be compelling evidence 
that the infection was related to the invasive device or procedure; 5. Associated with neutropenia (< 0.5 
* 109/L) contributed to by cytotoxic therapy; 6. The patient resided in a nursing home.   A community 
acquired infection (CAI) is defined as a positive culture obtained at the time of hospital admission or 
within the first 48 hours after admission which does not fit the criteria for a HCAI (14).  Underlying  
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disease refers to all conditions present at admission and diagnosed with up to 48 hours of the BSI.  The 
definition of source of infection were modified from Centres for  Disease Control and Prevention 
definitions(15).  The source of bacteraemia was divided into two categories: low risk, including BSI’s 
of urinary tract and vascular catheter origins and high risk including all other sources.  Antibiotic 
therapy was divided into 4 cohorts.  The empirical therapy cohort (ETC) included those patients who 
received an active agent against P. aeruginosa that was considered adequate based on analysis of the  
antibiogram of the isolate causing the infection in each episode.  Beta-lactam/beta-lactamase inhibitor 
therapy (BLBLI) excluding amoxicillin-calavulanate, carbapenem therapy excluding ertapenem, 
ceftazidime, cefepime and ciprofloxacin (intravenous) were considered acceptable.  This therapy 
needed to start within 24 hours of the blood culture being drawn; the antibiotic had to have been 
administered for at least 48 hours, with the single exception of patients who died before 48 hours, who 
were included if death occurred after 1 complete day of therapy with the assigned regimen.  The 
targeted therapy cohort (TTC) included patients who received an active agent against P. aeruginosa 
based on the susceptibility profile of the isolate.  Targeted therapy had to have started within 5 days of 
the blood culture being drawn and to be administered for at least 5 days. For patients who died while 
on targeted therapy, only those who died after at least 1 complete day of therapy with the targeted 
regimen were included.  Patients with the above criteria who continued with the same therapy that had 
been administered empirically once susceptibility results became available were also included in the 
TTC.  The utilisation of oral therapy was also looked at by the identification of patients who made a 
rapid change to oral therapy (RCOT) or made a late change to oral therapy (LCOT).   The RCOT 
cohort included any patient who received targeted therapy with the above criteria but the targeted 
therapy included a change to oral ciprofloxacin within the first 5 days of targeted therapy. The LCOT 
cohort included any patient who after a minimum of 5 days of targeted intravenous therapy had 
received at least 2 days of oral ciprofloxacin in the second 5 day phase of potential antibiotic therapy.  
If the patient had been rapidly changed to oral ciprofloxacin as per the RCOT cohort they were 
excluded from this group.  Recurrent infection was defined as subsequent culture of P. aeruginosa 
outside the primary BSI episode.  Mortality referred to all-cause mortality.  
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Microbiological Methods 
During the study period the blood cultures were processed by the BACTEC system (Becton Dickinson 
Microbiology Systems) with an incubation period of 5 days.  Isolates were identified by the VITEK 2 
system (bioMerieux, Balmes-les-Grottes, France).  Antimicrobial susceptibility testing was performed 
by a microdilution method on the VITEK 2 system. Clinical and Laboratory Standards Institute (CLSI) 
breakpoints for each year of the study were used to define susceptibility or resistance to the 
antimicrobial agents tested.   
 
 
 
Statistical analysis 
Variables with greater than 10% of missing data were excluded from the analysis to allow inclusion of 
the maximal number of patient episodes in the mortality analysis.  To prevent over fitting of data 
variables with less than 10% of the cohort having the presence of that factor were also excluded.  The 
relationship between mortality and categorical variables were compared using the chi-square test.  The  
student’s t test was used for continuous variables.  To identify independent risk factors for mortality, 
variables with a p value of < 0.2 on the univariate analysis were included in a backward stepwise 
multivariate logistic regression model. The variable was also required to make clinical sense to be 
included in the model. The fit of the model was assessed by the standardized Pearson test.   The 
analysis was done using Stata software (version 13; StataCorp LP).  
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Results 
This study retrospectively reviewed 595 episodes of P. aeruginosa BSI from 7 tertiary care hospitals in 
the city of Brisbane, a capital city of Australia, over a 3 year period.  Of the total number of episodes, 
207  episodes were excluded as they did not fit the defined criteria for inclusion: age less than 18 years 
(6), the blood culture growth was poly-microbial (excluding skin flora) or there was growth of another 
significant blood pathogen from 10 days prior to 14 days after the collection of the sentinel blood 
culture (132), the patient was not admitted to hospital post blood culture collection (8), the sentinel 
blood culture was not taken at a participating hospital (2), there was no antibiotic treatment of the 
blood culture isolate (4), the patient was transferred to another institution within 72 hours of the 
primary blood culture being collected (4), patient’s case notes could not be obtained  (21) or an episode 
of recurrent infection (30).    This left 388 individual patient BSI episodes for analysis.  
 
Characteristics of the Patient Population with P. aeruginosa BSI 
The clinical and demographic characteristics of the patients are outlined in Table 1.  Sixty percent of 
infections were hospital acquired.  Twelve percent of infections were CAI. Only 5% of the episodes 
involved patients in the ICU at the time of collection of the primary blood culture, the majority of 
patients being in the ward setting at time of specimen collection.  The median CCI was 2 (range 0-9). 
Thirty six percent of the patients had a haematological comorbidity, 19% an oncological comorbidity 
and 4% an autoimmune comorbidity.  There were only 26 patients with an organ or bone marrow 
transplant in the cohort. Two hundred and twenty one patients (57%) had received medical treatment in 
the 30 days prior in which the predominant therapy received was either chemotherapy or 
corticosteroids.  Twenty four percent of the cohort had been neutropenic in the preceding 14 days and 
20% had undergone surgery in the same time period.  Seventy eight percent of the cohort had a medical 
device in the preceding 7 days of which the most common was a vascular catheter followed by an 
indwelling urinary catheter. The source of infection could only be characterised in 139 of the patients 
in whom 16% were line related and 54% from the urinary tract.   The median Pitt bacteremia score for 
the BSI episodes was 1.   
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Only 14% of the cohort was still febrile and 14% hypotensive at 72 hours post collection of the sentinel 
blood culture. Twenty seven percent of the 271 patients for which this data could be obtained still had 
an elevated white cell count at 72 hours.   
 
The isolates of P. aeruginosa were highly sensitive with only 12 episodes containing a multidrug 
resistant isolate.16  Sixty one percent and 67% of the cohort received adequate empirical and targeted 
therapy according to the study definitions.  Forty seven BSI episodes received early oral ciprofloxacin 
treatment therapy and 47 episodes oral ciprofloxacin therapy in the second five days of the treatment 
course.   
 
Longitudinal Mortality of P. aeruginosa BSI 
Seventeen patients (4%) of the 388 patient cohort with P. aeruginosa BSI had died by 48 hours post 
collection of the sentinel blood culture.  This mortality rate increased over time with 11% of patients 
having deceased at 7 days, 19% having deceased by 28 days and 38% of patients having deceased at 
one year.  Sixty eight of these patients died while in hospital.  Table 2 shows the variables associated 
with death on multivariate analysis at each of the time points studied.  At 48 hours having a pulmonary 
comorbidity, corticosteroid therapy, a non-hospital acquired infection and a Pitt bacteremia score 
greater than 2 were the most significant variables associated with death. At one year female sex, a 
haematological or oncological comorbidity, a CCI of greater than 2 and corticosteroid therapy were 
associated with death.    
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Discussion  
This study showed an increasing rate of death out to one year post sentinel blood culture collection for 
patients who have had a P. aeruginosa BSI.  The percentage of death in our cohort increased from 4% 
at 48 hours to 38% at one year consistent with studies on all-cause bacteremia longitudinal mortality. 
Early mortality was associated with a non-hospital acquired infection, a pulmonary co-morbidity, 
corticosteroids in the prior 30 days and a Pitt bacteremia score of greater than 2. The Pitt score was 
associated with death out to 28 days post infection.   From seven days onwards patient co-morbidities 
became increasingly important.   
 
The majority of P. aeruginosa BSI studies have focused on all-cause mortality at one month post 
infection and describe mortality rates of up to 42% .1-5   Our study found that the longitudinal all-cause 
mortality associated with P. aeruginosa BSI increased with time post infection. We found a mortality 
rate of 4% at 48 hours that had increased to 38% at 1 year.  Al-Hasan looked at all-cause mortality  in 
P. aeruginosa BSI  and found a death rate of  25.5%  at 28 days which increased to 47.5% at one year.6   
This supports our findings.  Lillie et al looked at all-cause bacteremia and all-cause mortality out to 3 
years post a BSI.  They found that the rate of mortality increased from 15% at 30 days to 48.75% at 3 
years.9   
 
A number of  variables have been found to be associated with mortality at one month post P. 
aeruginosa  BSI infection including increasing age, BSI in the ICU setting, nosocomial acquisition, 
shock on presentation, inappropriate empirical drug therapy, corticosteroid use, high risk source of  
infection (defined as all BSI sources apart from urinary tract, vascular catheter, pancreatobiliary), 
antimicrobial resistance, polymicrobial infection and specific comorbidities such as cancer, cirrhosis 
and HIV.1,2,4,17-22   Early all-cause mortality, at 48 hours, in our study on multivariate analysis was 
associated with a non-hospital acquired infection, a pulmonary comorbidity, corticosteroid use and a 
Pitt bacteremia score greater than 2.  Explanation as to how these factors could contribute to a death 
related to infection in the acute setting is possible.  However further out from this period how does one 
interpret the associations found?  In our study the comorbidity burden became increasingly important  
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from 7 days post sentinel blood culture collection. A CCI of greater than 2 was found to be 
significantly associated with all-cause mortality out to one year post sentinel blood culture collection.  
A haematological co-morbidity, oncological co-morbidity and neutropenia within the prior 14 days to 
BSI were associated with mortality after 7 days post the BSI.   Corticosteroid therapy in the 30 days 
preceding BSI was important at 48 hours post BSI and then from 7 days onwards posts BSI. Female 
sex also became significantly associated with mortality at one year post the BSI.  It is difficult to 
distinguish between the variables that are independent from the acute disease process and those that are 
directly involved in the pathophysiology of the infective process leading to mortality.  
 
In an attempt to further define the role of infection and control for co-morbidities Leibovici et al looked 
at survival out to 4 years following all bacteraemia or fungaemia and compared survival to a control 
group without infection.  Each patient in the study was matched to a control patient based on age, sex, 
department and date of hospitalisation and the presence and absence of the following co-morbidities:  
solid malignancy, haematological malignancy, diabetes mellitus, congestive heart failure, chronic or 
acute renal failure, atherosclerotic heart disease, valvular disease, cerebrovascular accident, cirrhosis, 
cytotoxic treatment, burns and multiple trauma.   They found the mortality rate  was significantly 
higher at all-time points assessed, out to four years in the group with infection in comparison to the 
control group.23   Davis et al prospectively looked at outcomes to 5 years following hospital admission 
for sepsis using relative survival analysis.8  Australian life tables were used as the reference population.  
They found that mortality based on cumulative relative survival of the whole cohort exceeded that of 
the reference population for the first two years post admission in the whole cohort.  Quartin et al have 
shown also that sepsis increased the risk of death for up to five years after a septic episode even  if 
comorbidities were accounted for.24  In our study the median CCI was 2.  In the original study by 
Charlson et al, a CCI of 1-2 correlated with a death rate of 26% at one year.12 In our study 36% of the 
patients had died at one year which is above what would be predicted by the median CCI score for the 
cohort.   
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Nielsen et al looked at the specific cause attributed to death over a 12 year period in all-cause 
bacteremias.  In a population based cohort study they used the Danish cause of death register for 
attribution.   They found a significantly increased all-cause mortality rate ratio out to ten years in the  
patients with a bacteremia. They found that cardiovascular disease and malignancy were the most 
common cause of death post bacteremia.  In their cohort an infectious diseases cause of death 
accounted for only 5% of deaths at 0-1 year and 2.1% of deaths after one year.7   The difficulties of 
clinically defining cause or causes of death to write on a death certificate and its inaccuracies when 
compared to autopsy findings has previously been highlighted.25,26 
 
 
It is not clear if patients are dying from or with P. aeruginosa BSI.  Lillie et al in their all-cause 
bacteremia study looked for associations that may explain the later causes of death.  At 1 year they 
found increasing age and lower serum albumin predictive of death.   At 3 years they found increasing 
age, lower serum albumin, higher urea level and the presence of vascular disease predictive of death.  
They hypothesized that BSI may be a surrogate marker of risk of death from other causes or may 
precipitate or deteriorate certain disease states such as vascular disease giving rise to the rates of  later 
stage mortality seen.9  It is important to note that P. aeruginosa only made up a small number of the 
infections contributing to this cohort.   P. aeruginosa is a highly aggressive pathogen and how this 
would alter the biochemical markers discussed is not known.   
 
Future studies in the setting of P. aeruginosa BSI should ideally utilise matching of key variables such 
as age, sex and co-morbidities for patients to prevent excess attribution of death to infection.  Although 
prospective studies may allow a calculated assessment at the time of death whether infection played a 
role in the eventual outcome, this is really only applicable in the short term setting.  When looking at 
longer term mortality it may be impossible to attribute mortality to bacteremia due to other active co-
morbidities that might exist.  A better understanding of the pathophysiological mechanism of how a 
bacteremia would potentially cause long term mortality is also required to allow assessment of these 
factors.  
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There are a number of limitations of this study.  It is a retrospective cohort study and as such has 
potentially hidden biases.  In 21episodes the case notes could not be obtained and the patients were 
excluded from the study. There was greater than 10% of the cohort with missing data from the  
variables of bedside markers of infection and antibiotic treatment and as such these variables were not 
included in the analysis.  Length of bacteraemia was also not able to be characterised due to the almost 
complete absence of sequential blood cultures in the cohort.  The source of infection was only able to 
be identified in 36 % of the cohort and thus was not included in the analysis.  This was due to the low 
rate of source site sampling performed within the specified time period and the strict definition of 
source of infection used.  The breakpoints utilised by the laboratories involved in the study were prior 
to the European Committee of Antimicrobial Susceptibility Testing (EUCAST) and the Clinical 
Laboratory Standards Institute (CLSI) lowering the beta-lactam breakpoints in 2012.27,28 As such, there 
might be higher rates of resistance than this study has reported according to the later version of 
breakpoints now in use.    
 
In conclusion the longitudinal all-cause mortality of  P. aeruginosa BSI increased over time.  The 
mortality rate was 4% at 48 hours, 11% at 7 days, 19% at 30 days and increased to 38% at one year.  
Early mortality at 48 hours was associated with a non-hospital acquired infection, a pulmonary co-
morbidity, corticosteroid therapy and a Pitt bacteremia score greater than 2.  At one year female sex, a 
CCI greater than 2, a haematological or oncological co-morbidity as well as corticosteroid therapy were 
significantly associated with death.   As we better understand the pathophysiology of late mortality in 
the setting of BSI there may be other biochemical markers we can utilise to determine the degree to 
which infection is contributing.  Long term mortality in the setting of P. aeruginosa BSI needs to be 
studied further so we can determine if we are dying from or with this infection.  
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Table 1: Demographic, clinical and microbiological characteristics of the 388 episodes of                     
Pseudomonas aeruginosa bloodstream infection 
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Table 2: Risk factors for mortality in the setting of Pseudomonas aeruginosa bloodstream infection 
over time 
 
 
Confidence Interval p value CI p value CI p value CI p value
Age, mean (range in years)
Gender
Male 0.50 (0.29 - 0.75) <0.05
Acquistion
Non Hospital Acquired 8.38 (2.16 - 32.56) < 0.05 2.22 (1.10-4.45) <0.05
Co-morbidities
Central nervous system
Cardiovascular system
Pulmonary 5.05 (1.62 - 15.73) <0.05
Kidney
Gastrointestinal tract
Rheumatological
Hematological 2.36 (1.40 - 3.97) <0.05
Oncological 2.50 (1.34 - 4.60) <0.05
Diabetes 0.20 (0.05-0.73) <0.05 0.43 (0.19 - 0.98) <0.05 0.43 (0.22 - 0.85) <0.05
CCI >2 4.27 (2.09 - 8.68) <0.05 3.67 (2.07-6.53) <0.05 3.07 (1.83 (5.15) <0.05
Medical device prior 7 days
Vascular catheter
Indwelling urinary catheter
Prosthesic Material 
Medical treatment 30 days prior
Chemotherapy
Corticosteroids 5.01 (1.56 - 16.04) <0.05 1.81 (1.02 - 3.20) <0.05 1.98 (1.21 - 3.23) <0.05
Neutropenia prior 14 days 3.42 (1.67 - 7.02) <0.05 2.83 (1.56-5.14) <0.05
Pitt Bacteremia Score > 2 6.13 (1.97 - 19.07) <0.05 2.81 (1.30 - 6.10) <0.05 2.11 (1.11 - 4.05) <0.05
Antibiotic Susceptibility
Timentin resistant
48 Hours 7 Days 28 Days 1 Year
Variable
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